Ireland - English - HPRA (Health Products Regulatory Authority)

boehringer ingelheim limited - orciprenaline sulfate bromhexine hydrochloride - oral suspension - 10/4 mg /5m mg/5ml

Australia - English - Department of Health (Therapeutic Goods Administration)

natural force ( aust) pty ltd - ascorbic acid,avena sativa,calcium pantothenate,nicotinamide,panax ginseng,pyridoxine hydrochloride,tribulus terrestris,zinc sulfate monohydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - atenolol, quantity: 50 mg - tablet, film coated - excipient ingredients: magnesium carbonate hydrate; sodium starch glycollate type a; colloidal anhydrous silica; maize starch; sodium lauryl sulfate; magnesium stearate; hypromellose; macrogol 6000; titanium dioxide; purified talc - atenolol is indicated in the management of:,(i) all grades of hypertension, including hypertension of renal origin. (ii) frequent disabling angina without evidence of cardiac failure. (iii) cardiac arrhythmias (acute treatment of supraventricular and ventricular arrhythmias including those associated with acute myocardial infarction), (iv) myocardial infarction - late intervention (beta-blocker class effect greater than 12 hours after onset of chest pain)

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - atenolol, quantity: 50 mg - tablet, film coated - excipient ingredients: magnesium carbonate hydrate; sodium starch glycollate type a; colloidal anhydrous silica; maize starch; sodium lauryl sulfate; magnesium stearate; hypromellose; macrogol 6000; titanium dioxide; purified talc - atenolol is indicated in the management of:,(i) all grades of hypertension, including hypertension of renal origin. (ii) frequent disabling angina without evidence of cardiac failure. (iii) cardiac arrhythmias (acute treatment of supraventricular and ventricular arrhythmias including those associated with acute myocardial infarction), (iv) myocardial infarction - late intervention (beta-blocker class effect greater than 12 hours after onset of chest pain)

Canada - English - Health Canada

boehringer ingelheim (canada) ltd ltee - orciprenaline sulfate - syrup - 10mg - orciprenaline sulfate 10mg - selective beta 2-adrenergic agonists

Canada - English - Health Canada

boehringer ingelheim (canada) ltd ltee - orciprenaline sulfate - tablet - 20mg - orciprenaline sulfate 20mg - selective beta 2-adrenergic agonists

Canada - English - Health Canada

boehringer ingelheim (canada) ltd ltee - orciprenaline sulfate - liquid - 50mg - orciprenaline sulfate 50mg - selective beta 2-adrenergic agonists

Canada - English - Health Canada

boehringer ingelheim (canada) ltd ltee - orciprenaline sulfate - aerosol - .75mg - orciprenaline sulfate .75mg - selective beta 2-adrenergic agonists

Canada - English - Health Canada

technilab pharma inc. - orciprenaline sulfate - syrup - 10mg - orciprenaline sulfate 10mg - selective beta 2-adrenergic agonists

Australia - English - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - atenolol, quantity: 50 mg - tablet, film coated - excipient ingredients: pregelatinised maize starch; hypromellose; sodium starch glycollate; colloidal anhydrous silica; microcrystalline cellulose; sodium lauryl sulfate; magnesium stearate; titanium dioxide; indigo carmine; methylcellulose; macrogol 400 - atenolol is indicated in the management of: 1. all grades of hypertension, including hypertension of renal origin. 2. frequent disabling angina without evidence of cardiac failure. 3. cardiac arrhythmias (maintenance treatment of supraventricular and ventricular arrhythmias, including those associated with acute myocardial infarction). 4. myocardial infarction: late intervention (beta-blocker class effect greater than 12 hours after onset of chest pain).